- Status:
- National Phase Entry in US, KR
- Publication number:
- WO 2022/180216
- Priority date:
- Inventor:
- CARLOS ANTONIO GARCIA PRIETO, Manel Esteller Badosa, Lorea Villanueva Legarda
- Applicant:
- FUNDACIÓ INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS, BARCELONA SUPERCOMPUTING CENTER - CENTRO NACIONAL DE SUPERCOMPUTACIÓN, INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS
Abstract
This invention relates to in vitro methods for predicting the response of a subject to autologous chimeric antigen receptor T-cell (CAR T-cell) therapy, the methods comprising determining the methylation status of one or more cytosines in CpG sites of CAR T-cells. There are also disclosed means and kits for carrying out the methods. With the determination of the methylation status of the one or more cytosines in CpG sites, a complete response free of events and long overall survival can be predicted as an outcome of the CAR T-cell therapy, in particular to subjects with B-cell malignancies.
License conditions
- Type of licence: exclusive licence
- License royalties: between 3%-5% depending on the revenues
- Ownership of technology: INSTITUT JOSEP CARRERAS 69,9 % ICREA 13,6 % BSC-CNS 16,5 %
- Better fortune clause
- Ownership of the future innovation rights, depending on by who has been developed
- Applicable law would be Spanish and Barcelona jurisdiction.
TIME LIMIT TO APPLY: 15th May 2024
Patent family
- United States of America
- Republic of Korea